WO2001036394A1 - 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer - Google Patents
4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer Download PDFInfo
- Publication number
- WO2001036394A1 WO2001036394A1 PCT/US2000/031188 US0031188W WO0136394A1 WO 2001036394 A1 WO2001036394 A1 WO 2001036394A1 US 0031188 W US0031188 W US 0031188W WO 0136394 A1 WO0136394 A1 WO 0136394A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dimethoxyquinazoline
- hydroxyphenyl
- amino
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the present invention relates to quinazoline compounds, compositions and therapeutic methods for the treatment of cancers by administering quinazoline compounds.
- Quinazoline compounds have been suggested as useful compounds in the treatment of cell growth and differentiation characterized by activity of the human epidermal growth factor receptor type2 (HER2). See, for example, Myers et.al., U.S. Patent No. 5,721,237.
- Some quinazoline derivatives have been suggested as useful as anti-cancer agents for the treatment of specific receptor tyrosine kinase-expressing cancers, especially those expressing epithelial growth factor (EGF) receptor tyrosine kinase. See, for example, Barker et. al., U.S. Patent No. 5,457,105.
- quinazolines exert their anti-tumor effects via tyrosine kinase inhibition.
- some quinazoline compounds inhibit the growth of tumor cells, such as brain tumor cells, others with equally potent tyrosine kinase inhibitory activity fail to do so (Naria et.al., 1998, Clin.Cancer Res. 4:1405-1414; Naria et.al., 1998, Clin.Cancer Res. 4:2463-2471).
- quinazoline derivatives have also been suggested as useful agents for treating precancerous legions and inhibiting the growth of neoplastic cells. See for example, Pamukeu et al., U.S. Patents Nos. 5,990,117; 6,037,345; and 6,046,206. Although many of the disclosed quinazoline derivatives are useful for treating precancerous legions and inhibiting the growth of neoplastic cells, there still exists the need to discover better compounds for the treatment of cancer, in particular colorectal cancer.
- Cancer of the colon and/or rectum is now the third most common cause of death from cancer in the United States. Over 150,000 new cases of colon and/or rectal cancer are diagnosed each year. In addition, the incidence of colon cancer reportedly increases with age, particularly after the age of 40. Since the mean ages of populations in America and Western Europe are increasing, the prevalence of colorectal cancer should increase in the future.
- the present invention provides a method of preventing the development or recurrence of colorectal cancer in a mammal comprising administering to the mammal, an effective cancer preventative amount of 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline, or a pharmaceutically acceptable salt thereof.
- the present invention also provides the use of 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline, or a pharmaceutically acceptable salt thereof, to prepare a medicament useful for preventing the development or recurrence of colorectal cancer in a mammal.
- 4-(4'-hydroxyphenyl)amino- 6,7-dimethoxyquinazoline possesses increased activity against colorectal cancer.
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline is particularly useful as an active agent for anticancer compositions and for methods of treating cancers, such as colorectal cancer. Definitions
- pharmaceutically acceptable carrier means any material which, when combined with 4-(4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline, allows 4-(4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline to retain biological activity, such as the ability to potentiate antibacterial activity of mast cells and macrophages.
- examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsions, and various types of wetting agents. Compositions comprising such carriers are formulated by well- known conventional methods (see, for example, Remington's Pharmaceutical Sciences, Chapter 43, 14th Ed., Mack Publishing Co., Easton, PA).
- conjugate means a compound formed as a composite between two or more molecules. More specifically, in the present invention, 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline is bonded, for example, covalently bonded, to cell-specific targeting moieties forming a conjugate compound for efficient and specific delivery of 4-(4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline to a cell of interest.
- targeting moiety means a molecule, which serves to deliver 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to a specific site for the desired activity.
- Targeting moieties include, for example, molecules that specifically bind molecules on a specific cell surface.
- Such targeting moieties useful in the present invention include anti-cell surface antigen antibodies.
- Cytokines, including interleukins and factors such as granulocyte/macrophage stimulating factor (GMCSF) are also specific targeting moieties, known to bind to specific cells expressing high levels of their receptors.
- prodrug moiety is a substitution group, which facilitates use of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, for example by facilitating entry of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline into cells or administration of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline.
- the prodrug moiety may be cleaved from 4-(4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline, for example by cleavage enzymes in vivo.
- prodrug moieties include phosphate groups, peptide linkers, and sugars, which moieties can be hydrolyzed in vivo.
- inhibit means to reduce by a measurable amount, or to prevent entirely.
- to treat means to inhibit or block at least one symptom that characterizes a pathologic condition, in a mammal threatened by, or afflicted with, the condition.
- Compounds for use in the present invention include 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline, or pharmaceutically acceptable salts thereof.
- Pharmaceutically acceptable salts of 4-(4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline may include organic acid addition salts formed with acids, which form a physiological acceptable anion, including, but not limited to, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate, and a-glycerophosphate.
- Suitable inorganic salts may also be formed, including, but not limited to, hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
- Acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline useful in the present invention may be synthesized from a key starting material, 4-chloro-6,7- dimethoxyquinazoline, prepared using published procedures (Nomoto, et al., 1990, Chem. Pharm. Bull, 38:1591-1595; Thomas, C. L., 1970, Academic Press, New
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline may be useful as a pharmaceutical composition prepared with a therapeutically effective amount of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline and a pharmaceutically acceptable carrier or diluent.
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline may be formulated as a pharmaceutical composition and administered to a mammalian host, such as a human patient, in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier, or by inhalation or insufflation.
- a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier, or by inhalation or insufflation.
- the components may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
- 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline may be combined with a fine inert powdered carrier and inhaled by the subject or insufflated.
- Such compositions and preparations preferably contain at least 0.1 wt% of 4-(4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline.
- the percentage of 4-(4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline within a composition or preparation may, of course, be varied and may conveniently be between about 2 to about 60 wt% of a given unit dosage form.
- the amount of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline in such therapeutically useful compositions is such that an effective dosage level will be obtained.
- the tablets, troches, pills, capsules, and the like may also contain one or more of the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as com starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring.
- a liquid carrier such as a vegetable oil or a polyethylene glycol.
- any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non- toxic in the amounts employed.
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline may be incorporated into sustained-release preparations and devices. Further, 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline may be administered intravenously or intraperitoneally by infusion or injection. Solutions of 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline may be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical dosage forms suitable for injection or infusion may include sterile aqueous solutions or dispersions or sterile powders comprising 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
- the ultimate dosage form must be sterile, fluid and stable under the conditions of manufacture and storage.
- the liquid carrier or vehicle may be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
- a polyol for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like
- vegetable oils nontoxic glyceryl esters, and suitable mixtures thereof.
- suitable mixtures thereof may be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
- the prevention of the action of microorganisms may be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, buffers or sodium chloride.
- Prolonged absorption of the injectable compositions may be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions may be prepared by incorporating 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
- sterile powders for the preparation of sterile injectable solutions
- the preferred methods of preparation are vacuum drying and freeze drying techniques, which yield a powder of 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline plus any additional desired ingredient present in the previously sterile-filtered solutions.
- Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Other solid carriers include nontoxic polymeric nanoparticles or microparticles.
- Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which 4-(4'- hydroxyphenyl)amino-6,7-dimethoxyquinazoline can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
- the concentration of 4-(4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline in a liquid composition will be from about 0.1 to about 25 wt%, preferably from about 0.5 to about 10 wt%.
- the concentration of 4-(4'- hydroxyphenyl)amino-6,7 -dimethoxyquinazoline in a semi-solid or solid composition such as a gel or a powder will be about 0.1 to about 5 wt%, preferably about 0.5 to about 2.5 wt%.
- Dosage Of4-(4 '-hydroxyphenyl)amino-6, 7 -dimethoxy quinazoline The amount of 4-(4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline required for use in a given treatment will vary depending on a number of factors including, but not limited to, the route of administration, the nature of the condition being treated, and the age and condition of the patient. The amount of a given dosage will be ultimately at the discretion of the attendant physician or clinician. In general, however, a suitable dose will be in the range of from about 0.1 mg/kg to about 100 mg/kg of body weight per day.
- the dose will range from about 10 to about 75 mg/kg of body weight per day, more preferably from about 3 to about 50 mg/kg of body weight per day, even more preferably from about 6 to about 90 mg/kg of body weight per day, and even more preferably from about 15 to 60 mg/kg of body weight per day.
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline is conveniently administered in unit dosage form; for example, containing from about 5 to about 1000 mg, preferably from about 10 to about 750 mg, and more preferably from about 50 to about 500 mg of active ingredient per unit dosage form.
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline is administered to achieve peak plasma concentrations of from about 0.5 to about 75 ⁇ M, preferably from about 1 to about 50 ⁇ M, and more preferably from about 2 to about 30 ⁇ M.
- This may be achieved, for example, by the intravenous injection of a 0.05 to 5 wt% solution of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, optionally in saline, or orally administered as a bolus containing about 1 to 100 mg of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline. Desirable blood levels may be maintained by continuous infusion to provide about 0.01 to about 5.0 mg/kg/hr or by intermittent infusions containing from about 0.4 to about 15 mg/kg of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline.
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
- the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations, such as multiple inhalations from an insufflator.
- 6,7-dimethoxyquinazoline may be targeted to cells where treatment is desired, in particular, to colorectal cells.
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline may be targeted to the desired cell by conjugation to a targeting moiety that specifically binds to the desired cell, thereby directing administration of a conjugated molecule.
- Useful targeting moieties are ligands, which specifically bind cell antigens or cell surface ligands, for example, antibodies against the B cell antigen, CD 19 (such as B43) and the like.
- targeting moieties are covalently bonded to sites on 4-(4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline.
- the targeting moiety which is often a polypeptide molecule, is bound to 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline at reactive sites, including, but not limited to, OH, and the like.
- Specific linking agents are used to join the compounds. Preferred linking agents are chosen according to the reactive site to which the targeting moiety is to be attached.
- the ability of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent the development or recurrence of a cancer may be determined using pharmacological models, which are well known to the art, or using the methods as described herein.
- preventing the development or recurrence includes both slowing the development or recurrence, as well as completely eliminating the development or recurrence.
- 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline was prepared by the condensation of 4-chloro-6,7-dimethoxyquinazoline with 4-aminophenol as outlined below in Scheme 2 above.
- Example 2 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline was synthesized as described in Example 1 and characterized. The structure is shown below, along with its identifying analytical test results. Proton and carbon Nuclear Magnetic Resonance ( ⁇ and 13 C NMR) spectra were recorded on a Mercury 2000 Varian spectrometer operating at 300 MHz and 75 MHz, respectively, using an automatic broad band probe. Unless otherwise noted, all NMR spectra were recorded in CDC1 3 at room temperature.
- the infrared spectra of the liquid samples were run as neat liquids using KBr discs.
- the KBr pellet method was used for all solid samples.
- the GC/mass spectrum analysis was conducted using a Hewlett-Packard GC/mass spectrometer model # 6890 equipped with a mass ion detector and Chem Station software. The temperature of the oven was steadily increased from 70°C to 250°C and the carrier gas was helium.
- mice were fed rodent chow without 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. The health status of the mice was monitored for thirty weeks. Table 1 below describes the Probability of Survival for each group of mice over a period of 210 days.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002391396A CA2391396A1 (en) | 1999-11-15 | 2000-11-14 | 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
JP2001538883A JP2003514803A (en) | 1999-11-15 | 2000-11-14 | 4- (4'-Hydroxyphenyl) amino-6,7-dimethoxyquinazoline for preventing the development of colorectal cancer |
EP00977201A EP1232146A1 (en) | 1999-11-15 | 2000-11-14 | 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
AU14870/01A AU1487001A (en) | 1999-11-15 | 2000-11-14 | 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
US10/145,639 US6482828B1 (en) | 1999-11-15 | 2002-05-14 | 4-(4′-hydroxyphenyl) amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16549999P | 1999-11-15 | 1999-11-15 | |
US60/165,499 | 1999-11-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/145,639 Continuation US6482828B1 (en) | 1999-11-15 | 2002-05-14 | 4-(4′-hydroxyphenyl) amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001036394A1 true WO2001036394A1 (en) | 2001-05-25 |
Family
ID=22599158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/031188 WO2001036394A1 (en) | 1999-11-15 | 2000-11-14 | 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1232146A1 (en) |
JP (1) | JP2003514803A (en) |
AU (1) | AU1487001A (en) |
CA (1) | CA2391396A1 (en) |
WO (1) | WO2001036394A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797721B2 (en) | 1999-11-15 | 2004-09-28 | Parker Hughes Institute | Phorboxazole derivatives for treating cancer |
KR20160015113A (en) * | 2014-07-30 | 2016-02-12 | 원광대학교산학협력단 | Composition for preventing and treating osteoporosis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
WO1999061428A1 (en) * | 1998-05-28 | 1999-12-02 | Parker Hughes Institute | Quinazolines for treating brain tumor |
WO2000056720A1 (en) * | 1999-03-19 | 2000-09-28 | Parker Hughes Institute | Quinazolines and therapeutic use thereof |
-
2000
- 2000-11-14 AU AU14870/01A patent/AU1487001A/en not_active Abandoned
- 2000-11-14 CA CA002391396A patent/CA2391396A1/en not_active Abandoned
- 2000-11-14 JP JP2001538883A patent/JP2003514803A/en not_active Withdrawn
- 2000-11-14 EP EP00977201A patent/EP1232146A1/en not_active Withdrawn
- 2000-11-14 WO PCT/US2000/031188 patent/WO2001036394A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
WO1999061428A1 (en) * | 1998-05-28 | 1999-12-02 | Parker Hughes Institute | Quinazolines for treating brain tumor |
WO2000056720A1 (en) * | 1999-03-19 | 2000-09-28 | Parker Hughes Institute | Quinazolines and therapeutic use thereof |
Non-Patent Citations (3)
Title |
---|
F.M.UCKUN: "IN VIVO TOXICITY A. PHARMACOKINETIC FEATURES OF THE JANUS KINASE3 INHIBITOR WHI-P131.", CLINICAL CANCER RESEARCH., vol. 5, October 1999 (1999-10-01), THE AMERICAN ASSOCIATION FOR CANCER RESEARCH., US, pages 2954 - 62, XP002165069, ISSN: 1078-0432 * |
P.GOODMAN ET AL.: "ROLE OF TYROSINE KINASE", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 273, no. 28, 10 July 1998 (1998-07-10), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., US, pages 17742 - 48, XP002122432, ISSN: 0021-9258 * |
RAMA KRISHNA NARLA: "INHIBITION OF HUMAN GLIOBLASTOMA CELL ADHESION", CLINICAL CANCER RESEARCH., vol. 4, no. 10, October 1998 (1998-10-01), THE AMERICAN ASSOCIATION FOR CANCER RESEARCH., US, pages 2463 - 71, XP002165068, ISSN: 1078-0432 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797721B2 (en) | 1999-11-15 | 2004-09-28 | Parker Hughes Institute | Phorboxazole derivatives for treating cancer |
KR20160015113A (en) * | 2014-07-30 | 2016-02-12 | 원광대학교산학협력단 | Composition for preventing and treating osteoporosis |
KR101632111B1 (en) | 2014-07-30 | 2016-06-20 | 원광대학교산학협력단 | Composition for preventing and treating osteoporosis |
Also Published As
Publication number | Publication date |
---|---|
AU1487001A (en) | 2001-05-30 |
JP2003514803A (en) | 2003-04-22 |
CA2391396A1 (en) | 2001-05-25 |
EP1232146A1 (en) | 2002-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4934432B2 (en) | Quinazoline derivatives and therapeutic use of quinazoline derivatives | |
EP0824525B1 (en) | Quinazoline derivatives | |
KR100296656B1 (en) | Quinazoline derivatives | |
US6258820B1 (en) | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines | |
EP0823901B1 (en) | Quinazoline derivative | |
EP0824526B1 (en) | Quinazoline derivative | |
US20110275643A1 (en) | Aroylquinoline compounds | |
JP2000505441A (en) | Quinazoline compounds | |
RU2594155C2 (en) | Novel compositions and methods of producing 5-amino- or substituted amino-1,2,3-triazoles and triazole-orotate compositions | |
EP2269994B1 (en) | The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof | |
US6482828B1 (en) | 4-(4′-hydroxyphenyl) amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer | |
CN103896863B (en) | Crystal formation of anticancer compound ZD1839 and preparation method thereof | |
WO2001036394A1 (en) | 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer | |
CN115803326A (en) | EGFR inhibitor, preparation method and pharmaceutical application thereof | |
CN107501283B (en) | Preparation of substituted arylmethyl hetero-substituted anilino ethylene glycol ether cycloquinazoline and application of tumor treatment drug | |
CN101898979B (en) | Phenyl nitrone compounds containing stilbene sections and application thereof | |
US20210053944A1 (en) | Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof | |
CN112279863A (en) | Conjugate of Hsp90 inhibitor and camptothecin derivative as well as preparation method and application thereof | |
EP3596054B1 (en) | 5-carboxamide-2-thiobarbituric acids and use thereof as medicaments | |
CN118201940A (en) | AKR1C3 activated DNA alkylating agent and medical application thereof | |
WO2001035952A2 (en) | Radiosensitization of human glioblastoma cells by quinazoline compounds | |
CN118063440A (en) | Antitumor application of 6-fluoroquinazoline compound | |
CN118063441A (en) | Preparation of aminoquinazoline compound and anti-tumor effect | |
CN116970029A (en) | Bridged ring compound, preparation method thereof and application thereof in medicine | |
CN114957137A (en) | N- (1,2,3, 6-tetrahydropyrimidine-4-yl) -2-phenyl acetamide compound and preparation and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 14870/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2391396 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 538883 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000977201 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000977201 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000977201 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |